Anti-PD1 armored CD19 CAR-T cells
Phase 1Cell therapy
Anti-PD1 armored CD19 CAR-T cells is one of 41 biologic programs targeting Diffuse Large B-Cell Lymphoma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
332 competitors in Diffuse Large B-Cell Lymphoma
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Rayos
RRoxane Laboratories
Phase 3
Adriamycin
GGynecologic Oncology Group
Phase 3
Oncovin
EEastern Cooperative Oncology Group
Phase 3
Trexall
Alnylam PharmaceuticalsPhase 3
Decadron
AAspen Global Incorporated
Phase 3
Leukine
SanofiPhase 3
Brukinsa
BBeOne Medicines
Phase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Alkeran
AApotex Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details